The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Amgen Research Munich competitive analysis

Loading summary...

Latest patents of Amgen Research Munich opposed by its competitors

Explore Amgen Research Munich's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents3
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
EP3531133
Aug 23, 2023Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1
EP3411402
Dec 22, 2021Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs1
EP3228315
Nov 25, 2020Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP3412687
Mar 18, 2020Methods For Treating Dlbcl1
EP2780375
Sep 11, 2019Binding Molecules For Bcma And Cd38
EP2780374
Aug 21, 2019Binding Molecules For Bcma And Cd37
EP3149480
Dec 26, 2018Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1

Latest PTAB cases involving Amgen Research Munich

Discover the latest PTAB cases involving Amgen Research Munich, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amgen Research Munich with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMGEN RESEARCH MUNICH - 30 - -
ABBVIE109 - 1
JAMES POOLE153 - - -
REGENERON PHARMACEUTICALS3894931